References
Alexander SPH, Mathie A, Peters JA, Veale EL, Striessnig J, Kelly
E, et al. (2019). THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Ion
channels. Br J Pharmacol 176 Suppl 1: S142-S228.
Alexander SPH, Roberts RE, Broughton BRS, Sobey CG, George CH, Stanford
SC, et al. (2018). Goals and practicalities of immunoblotting and
immunohistochemistry: A guide for submission to the British Journal of
Pharmacology. Br J Pharmacol 175: 407-411.
Belaid H, Adrien J, Karachi C, Hirsch EC, & Francois C (2015). Effect
of melatonin on sleep disorders in a monkey model of Parkinson’s
disease. Sleep Med 16: 1245-1251.
Bido S, Soria FN, Fan RZ, Bezard E, & Tieu K (2017). Mitochondrial
division inhibitor-1 is neuroprotective in the A53T-alpha-synuclein rat
model of Parkinson’s disease. Sci Rep 7: 7495.
Carter SJ, Durrington HJ, Gibbs JE, Blaikley J, Loudon AS, Ray DW,
et al. (2016). A matter of time: study of circadian clocks and their
role in inflammation. J Leukoc Biol 99: 549-560.
Celardo I, Martins LM, & Gandhi S (2014). Unravelling mitochondrial
pathways to Parkinson’s disease. Br J Pharmacol 171: 1943-1957.
Cho B, Choi SY, Cho HM, Kim HJ, & Sun W (2013). Physiological and
pathological significance of dynamin-related protein 1 (drp1)-dependent
mitochondrial fission in the nervous system. Exp Neurobiol 22:149-157.
Curtis MJ, Alexander S, Cirino G, Docherty JR, George CH, Giembycz
MA, et al. (2018). Experimental design and analysis and their
reporting II: updated and simplified guidance for authors and peer
reviewers. Br J Pharmacol 175: 987-993.
de Goede P, Wefers J, Brombacher EC, Schrauwen P, & Kalsbeek A (2018).
Circadian rhythms in mitochondrial respiration. J Mol Endocrinol
60: R115-r130.
Duty S, & Jenner P (2011). Animal models of Parkinson’s disease: a
source of novel treatments and clues to the cause of the disease. Br J
Pharmacol 164: 1357-1391.
Gong C, Li C, Qi X, Song Z, Wu J, Hughes ME, et al. (2015). The
daily rhythms of mitochondrial gene expression and oxidative stress
regulation are altered by aging in the mouse liver. Chronobiol Int
32: 1254-1263.
Harding SD, Sharman JL, Faccenda E, Southan C, Pawson AJ, Ireland
S, et al. (2018). The IUPHAR/BPS Guide to PHARMACOLOGY in 2018:
updates and expansion to encompass the new guide to IMMUNOPHARMACOLOGY.
Nucleic Acids Res 46: D1091-d1106.
Hayashi A, Matsunaga N, Okazaki H, Kakimoto K, Kimura Y, Azuma H,
et al. (2013). A disruption mechanism of the molecular clock in a MPTP
mouse model of Parkinson’s disease. Neuromolecular Med 15:238-251.
Holownia A, Chwiecko M, & Farbiszewski R (1994). Accumulation of
ammonia and changes in the activity of some ammonia metabolizing enzymes
during brain ischemia/reperfusion injury in rats. Mater Med Pol
26: 25-27.
Kim DH, Yoon BH, Jung WY, Kim JM, Park SJ, Park DH, et al.(2010). Sinapic acid attenuates kainic acid-induced hippocampal neuronal
damage in mice. Neuropharmacology 59: 20-30.
Kim J, Jang S, Choi M, Chung S, Choe Y, Choe HK, et al. (2018).
Abrogation of the Circadian Nuclear Receptor REV-ERBalpha Exacerbates
6-Hydroxydopamine-Induced Dopaminergic Neurodegeneration. Mol Cells
41: 742-752.
Kohsaka A, Das P, Hashimoto I, Nakao T, Deguchi Y, Gouraud SS, et
al. (2014). The circadian clock maintains cardiac function by
regulating mitochondrial metabolism in mice. PLoS One 9:e112811.
Laloux C, Derambure P, Houdayer E, Jacquesson JM, Bordet R, Destee
A, et al. (2008). Effect of dopaminergic substances on
sleep/wakefulness in saline- and MPTP-treated mice. J Sleep Res
17: 101-110.
Lauretti E, Di Meco A, Merali S, & Pratico D (2017). Circadian rhythm
dysfunction: a novel environmental risk factor for Parkinson’s disease.
Mol Psychiatry 22: 280-286.
Lee HE, Kim DH, Park SJ, Kim JM, Lee YW, Jung JM, et al. (2012).
Neuroprotective effect of sinapic acid in a mouse model of amyloid
beta(1-42) protein-induced Alzheimer’s disease. Pharmacol Biochem Behav
103: 260-266.
Lee SB, Youn J, Jang W, & Yang HO (2019). Neuroprotective effect of
anodal transcranial direct current stimulation on
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced
neurotoxicity in mice through modulating mitochondrial dynamics.
Neurochem Int 129: 104491.
Li E, Li X, Huang J, Xu C, Liang Q, Ren K, et al. (2020). BMAL1
regulates mitochondrial fission and mitophagy through mitochondrial
protein BNIP3 and is critical in the development of dilated
cardiomyopathy. Protein Cell.
Li X, Lin J, Ding X, Xuan J, Hu Z, Wu D, et al. (2019). The
protective effect of sinapic acid in osteoarthritis: In vitro and in
vivo studies. J Cell Mol Med 23: 1940-1950.
McGrath JC, & Lilley E (2015). Implementing guidelines on reporting
research using animals (ARRIVE etc.): new requirements for publication
in BJP. Br J Pharmacol 172: 3189-3193.
Mishra A, Singh S, Tiwari V, Bano S, & Shukla S (2019). Dopamine D1
receptor agonism induces dynamin related protein-1 inhibition to improve
mitochondrial biogenesis and dopaminergic neurogenesis in rat model of
Parkinson’s disease. Behav Brain Res 378: 112304.
Park J, Seo J, Won J, Yeo HG, Ahn YJ, Kim K, et al. (2019).
Abnormal Mitochondria in a Non-human Primate Model of MPTP-induced
Parkinson’s Disease: Drp1 and CDK5/p25 Signaling. Exp Neurobiol
28: 414-424.
Qi X, Qvit N, Su YC, & Mochly-Rosen D (2013). A novel Drp1 inhibitor
diminishes aberrant mitochondrial fission and neurotoxicity. J Cell Sci
126: 789-802.
Roby DA, Ruiz F, Kermath BA, Voorhees JR, Niehoff M, Zhang J, et
al. (2019). Pharmacological activation of the nuclear receptor REV-ERB
reverses cognitive deficits and reduces amyloid-β burden in a mouse
model of Alzheimer’s disease. PLoS One 14: e0215004.
Roe AJ, & Qi X (2018). Drp1 phosphorylation by MAPK1 causes
mitochondrial dysfunction in cell culture model of Huntington’s disease.
Biochem Biophys Res Commun 496: 706-711.
Shahmohamady P, Eidi A, Mortazavi P, Panahi N, & Minai-Tehrani D
(2018). Effect of sinapic acid on memory deficits and neuronal
degeneration induced by intracerebroventricular administration of
streptozotocin in rats. Pol J Pathol 69: 266-277.
Shirihai OS, Song M, & Dorn GW, 2nd (2015). How mitochondrial dynamism
orchestrates mitophagy. Circ Res 116: 1835-1849.
Stujanna EN, Murakoshi N, Tajiri K, Xu D, Kimura T, Qin R, et al.(2017). Rev-erb agonist improves adverse cardiac remodeling and survival
in myocardial infarction through an anti-inflammatory mechanism. PLoS
One 12: e0189330-e0189330.
Suen DF, Norris KL, & Youle RJ (2008). Mitochondrial dynamics and
apoptosis. Genes Dev 22: 1577-1590.
Ueda HR, Hayashi S, Chen W, Sano M, Machida M, Shigeyoshi Y, et
al. (2005). System-level identification of transcriptional circuits
underlying mammalian circadian clocks. Nat Genet 37: 187-192.
Videnovic A, & Golombek D (2013). Circadian and sleep disorders in
Parkinson’s disease. Exp Neurol 243: 45-56.
Wang Y, Lv D, Liu W, Li S, Chen J, Shen Y, et al. (2018).
Disruption of the Circadian Clock Alters Antioxidative Defense via the
SIRT1-BMAL1 Pathway in 6-OHDA-Induced Models of Parkinson’s Disease.
Oxid Med Cell Longev 2018: 4854732.
Welch RD, Billon C, Valfort AC, Burris TP, & Flaveny CA (2017).
Pharmacological inhibition of REV-ERB stimulates differentiation,
inhibits turnover and reduces fibrosis in dystrophic muscle. Sci Rep
7: 17142.
Woldt E, Sebti Y, Solt LA, Duhem C, Lancel S, Eeckhoute J, et al.(2013a). Rev-erb-alpha modulates skeletal muscle oxidative capacity by
regulating mitochondrial biogenesis and autophagy. Nat Med 19:1039-1046.
Woldt E, Sebti Y, Solt LA, Duhem C, Lancel S, Eeckhoute J, et al.(2013b). Rev-erb-α modulates skeletal muscle oxidative capacity by
regulating mitochondrial biogenesis and autophagy. Nat Med 19:1039-1046.
Xie Y, Tang Q, Chen G, Xie M, Yu S, Zhao J, et al. (2019). New
Insights Into the Circadian Rhythm and Its Related Diseases. Front
Physiol 10: 682.
Yang C, Deng Q, Xu J, Wang X, Hu C, Tang H, et al. (2019).
Sinapic acid and resveratrol alleviate oxidative stress with modulation
of gut microbiota in high-fat diet-fed rats. Food Res Int 116:1202-1211.
Yang S, Liu Y, Guo Y, Liu R, Qi F, Li X, et al. (2020). Circadian
gene Clock participates in mitochondrial apoptosis pathways by
regulating mitochondrial membrane potential, mitochondria out membrane
permeablization and apoptosis factors in AML12 hepatocytes. Mol Cell
Biochem 467: 65-75.
Ylikoski A, Martikainen K, Sieminski M, & Partinen M (2015).
Parkinson’s disease and insomnia. Neurol Sci 36: 2003-2010.
Yoon BH, Jung JW, Lee JJ, Cho YW, Jang CG, Jin C, et al. (2007).
Anxiolytic-like effects of sinapic acid in mice. Life Sci 81:234-240.
Zare K, Eidi A, Roghani M, & Rohani AH (2015). The neuroprotective
potential of sinapic acid in the 6-hydroxydopamine-induced
hemi-parkinsonian rat. Metab Brain Dis 30: 205-213.
Zheng JL, Yuan SS, Wu CW, Lv ZM, & Zhu AY (2017). Circadian
time-dependent antioxidant and inflammatory responses to acute cadmium
exposure in the brain of zebrafish. Aquat Toxicol 182: 113-119.
Figure 1 . Effect of SA in MPP+ SH-SY5Y cells.
(A) Evaluation of the dose-dependent effects of SA. (B) The protein
expression of TH was measured by western blot after treatment with both
MPP+ and SA. (C) The cellular ATP content and (D)
median GDH activity were measured using a commercially available assay
kit to examine mitochondrial function. The results are presented as the
mean\(\pm\)S.E.M. *P < 0.05 compared
to the control group, #p < 0.05
compared to the MPP+ group.
Figure 2 . Effect of SA in MPP+-treated
SH-SY5Y cells exposed to the REV-ERB α antagonist SR8278 and the REV-ERB
α agonist GSK4112. (A – C) The protein expression of REV-ERB α and TH
was measured by western blot after treatment with both
MPP+ and SA. The results are presented as the
mean\(\pm\)S.E.M. *P < 0.05 compared
to the control group, #p < 0.05
compared to the MPP+ group.
Figure 3 . Effect of SA in MPTP-treated mice. (A – B) After 5
days of SA treatment with or without MPTP, we examined the motor
function of mice using the rotarod test and the pole test. (C - D) The
cellular ATP content and GDH activity were measured using a commercially
available assay kit to examine mitochondrial function. (E - F) The
protein expression of TH and REV-ERB α was measured by western blot
after treatment with both MPTP and SA. (G) Images of TH (green), REV-ERB
α (red) and nuclei (blue) in the SNpc tissues were collected by
fluorescence microscopy. The results are presented as the
mean\(\pm\)S.E.M. *P < 0.05 compared
to the control group, #p < 0.05
compared to the MPTP group.
Figure 4 Effect of SA on mitochondrial fission in MPTP-treated
mice. (A - D) The protein expression of Drp1, phospho-Drp1 Ser616, and
phospho-Drp1 Ser637 was measured by western blot after treatment with
both MPTP and SA. The results are presented as the mean\(\pm\)S.E.M.*P < 0.05 compared to the control
group, #p < 0.05 compared to the
MPTP group.
Figure 5 . Effect of SA in MPTP-treated mice through inhibition
of REV-ERB α.
(A – B) After 5 days of SA and SR treatment with or without MPTP, we
examined the motor function of mice using the rotarod test and the pole
test. (C – D) The cellular ATP content and GDH activity were measured
using a commercially available assay kit to examine mitochondrial
function. (E – F) The protein expression of TH and REV-ERB α was
measured by western blot after treatment with MPTP, SA and SR. The
results are presented as the mean\(\pm\)S.E.M.*P < 0.05 compared to the control
group, #p < 0.05 compared to the
MPTP group, $p < 0.05 compared to
the SA group.
Figure 6 . Effect of SA on mitochondrial fission in MPTP-treated
mice through inhibition of REV-ERB α. (A – D) The protein expression of
Drp1, phospho-Drp1 Ser616, and phospho-Drp1 Ser637 was measured by
western blot after treatment with MPTP, SA and SR. The results are
presented as the mean\(\pm\)S.E.M. *P< 0.05 compared to the control group,#p < 0.05 compared to the MPTP
group, $p < 0.05 compared to the SA
group.